A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

Columbia University Medical Center (SCD subjects only), New York

University of Maryland, Greenebaum Comprehensive Cancer Center (SCD subjects only), Baltimore

Duke University Medical Center (SCD subjects only), Durham

Levine Cancer Institute (SCD subjects only), Charlotte

Children's Healthcare of Atlanta (SCD subjects only), Atlanta

Augusta University Medical Center (SCD subjects only), Augusta

Advanced Pharma CR, LLC (SCD subjects only), Miami

St. Jude Children's Research Hospital (SCD subjects only), Memphis

University of Cincinnati Medical Center (SCD subjects only), Cincinnati

Medpace Clinical Pharmacology Unit (Healthy Volunteers only), Cincinnati

Cincinnati Children's Hospital Medical Center (SCD subjects only), Cincinnati

University of Illinois at Chicago (SCD subjects only), Chicago

Woodland International Research Group (SCD subjects only), Little Rock

Lynn Institute of Tulsa (SCD subjects only), Tulsa

The University of Texas Health Science Center at Houston (SCD subjects only), Houston

Collaborative Neuroscience Research, LLC (SCD subjects only), Long Beach

Pacific Research Partners (SCD subjects only), Oakland

UCSF Benioff Children's Hospital Oakland (SCD subjects only), Oakland